Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Prevena device · 1 trial · 3 indications
The ASEPSIS quantitative wound scoring method will be used to assess patients' leg wound healing after saphenous vein harvesting for coronary artery bypass surgery.
| Arm | Type | Description |
|---|---|---|
| Prevena device (Group A) | EXPERIMENTAL | Group A will have the VAC Prevena portable device applied to the saphenous vein harvest site after standard wound closure following coronary artery bypass surgery. |
| Conventional dressing (Group B) | NO_INTERVENTION | Group B will have conventional dry dressing applied to the saphenous vein harvest site after standard wound closure following coronary artery bypass surgery. |
| Name | Type | Description |
|---|---|---|
| Prevena device (Group A) | DEVICE | This portable device is applied to initiate negative pressure therapy to a wound site. |
Inclusion Criteria: * Patients presenting for elective or semi-elective isolated first-time CABG surgery with harvesting of the greater saphenous vein. * Must be 18 years or older. * Must live with one hour driving distance from Calgary. * Must provide written consent. Exclusion Criteria: * Previ...
Top 8 of 16 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 4 | PHASE3 | Ziltivekimab |
| Novartis AG Sponsored ADR | NVS | 4 | PHASE3 | Inclisiran |
| Alnylam Pharmaceuticals, Inc | ALNY | 1 | PHASE3 | Zilebesiran |
| Viatris, Inc. | VTRS | 1 | PHASE3 | Selatogrel |
| NewAmsterdam Pharma Company N.V. | NAMS | 1 | PHASE3 | Obicetrapib |
| GE Healthcare Technologies Inc. | GEHC | 3 | PHASE1 | Regadenoson |
| AstraZeneca PLC | AZN | 1 | - | Tezepelumab |
| Sanofi SA Sponsored ADR | SNY | 1 | - | alirocumab |